Bayer, Hurdle launch precision health strategic partnership

This alliance integrates Hurdle's cutting-edge technology with Bayer’s consumer-focused product development expertise and global footprint. Through this alliance, Bayer will sell Hurdle’s saliva-based Chronomics Biological Age Test through direct-to-consumer e-commerce, with the shared goal of advancing precision health and the science behind measuring biological age through epigenetic biomarkers.

“Across cultures a consistent priority for people is better managing how they age,” said David Evendon-Challis, chief scientific officer and head of R&D for the Consumer Health division of Bayer. “While aging is common to us all in terms of time, how our bodies age on the inside is unique to each person and can be impacted by many factors including environment, lifestyle and genetics. Enabling people to better understand their unique place in this journey through scientific data is the first step to helping them take proactive steps in supporting their own cellular aging process.”

Tom Stubbs, CEO of Hurdle, commented, “Our partnership with Bayer marks a significant leap in precision health. At Hurdle, we've streamlined the complex journey from biomarker discovery to consumer meaningful products, thanks to our advanced technology and extensive network. Teamed up with Bayer's unmatched expertise in consumer health, we're poised to redefine and expedite self-care solutions. Together, we're championing precision health, prioritizing both speed and individualized solutions with the goal of advancing the science behind measuring biological age.”

"Hurdle's AI-powered epigenetics and multi-omics biomarker discovery engine stands at the forefront of this partnership, echoing Bayer's strategic direction towards precision health and the deployment of digital tools that allow for smarter health choices," the release stated.

Earlier this year, Bayer launched a new business unit focused on developing new precision consumer health products.